Tolerability of abacavir in the clinical setting

Clin Microbiol Infect. 2000 Nov;6(11):621-2. doi: 10.1046/j.1469-0691.2000.00162.x.
No abstract available

MeSH terms

  • Dideoxynucleosides / adverse effects*
  • Dideoxynucleosides / therapeutic use
  • Drug Synergism
  • HIV Infections / drug therapy*
  • Humans
  • No-Observed-Adverse-Effect Level
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Safety

Substances

  • Dideoxynucleosides
  • Reverse Transcriptase Inhibitors
  • abacavir